Monte Rosa Therapeutics, Inc. (GLUE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$164.8M
Cash & Equivalents
$37.4M
Quarterly Burn Rate
13 mo
Est. Cash Runway
$1,946M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (2)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT05546268 | Study of Oral MRT-2359 in Selected Cancer Patients | PHASE2 | Active Not Recruiting | 174 |
| NCT07119125 | A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated... | PHASE1 | Active Not Recruiting | 100 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.